Why CymoGen DxFluorescent In Situ hybridization technology, having been discovered in the early 1980’s and commercialized in 1990’s has not kept up with the fast changing pace of medical technology brought upon by the Human Genome Project. Current FISH methods for detecting chromosomal aberrations employed in research and commercial settings have a variety of limitations, and there is an increasing need for superior methods, systems and methods to detect aberrations. Probes should be compact, with better design that takes advantage of contemporary genomics, brighter through the use of advances in labeling techniques, while continuing to use current protocols and image analysis and filter infrastructure, all towards the goal of having greater analytical accuracy. Additionally, there is a need for robust FISH methods in the area of Formalin Fixed Paraffin Embedded solid tumor samples providing the ability to clearly detect aberrations and particularly deletions. NEXT-GEN FISH™ TECHNOLOGYCymoGen Dx’s Next-Gen Fish technology is a series of novel innovations creating products with unprecedented accuracy and improvements to a technology that has become the Gold Standard for identifying Genomic Instability, while utilizing current filters, equipment and protocols:
|
